Literature DB >> 26407384

Drug treatment of pruritus in liver diseases.

Vinod S Hegade1, Stuart F W Kendrick2, David E J Jones2.   

Abstract

Pruritus (itch) is a common complication of cholestatic liver diseases (CLD). It can be a distressing and debilitating symptom, causing significant impairment in quality of life. Treatment of pruritus in liver diseases can be challenging and requires specific management with early initiation and a step-wise approach using specific drugs. Clinical trials are ongoing with novel agents that demonstrate potential efficacy. Patients with cholestatic pruritus are likely to present to a variety of clinicians who would benefit from medical awareness of available treatment options. In this review, we outline the pharmaceutical agents currently used to treat cholestatic pruritus and provide the evidence base for targeted symptom control of itch in liver diseases. We also highlight recent developments in the pathophysiology of cholestatic pruritus and the emerging novel therapies. © Royal College of Physicians 2015. All rights reserved.

Entities:  

Keywords:  Pruritus; cholestasis; liver disease; primary biliary cirrhosis; treatment

Mesh：

Substances：

Year:  2015        PMID： 26407384      PMCID： PMC4952797          DOI： 10.7861/clinmedicine.15-4-351

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN： 1470-2118            Impact factor:   2.659


  24 in total

1.  Effects of long-term rifampicin administration in primary biliary cirrhosis.

Authors:  L Bachs; A Parés; M Elena; C Piera; J Rodés
Journal:  Gastroenterology       Date:  1992-06       Impact factor: 22.682

2.  Endogenous opioids accumulate in plasma in a rat model of acute cholestasis.

Authors:  M G Swain; R B Rothman; H Xu; J Vergalla; N V Bergasa; E A Jones
Journal:  Gastroenterology       Date:  1992-08       Impact factor: 22.682

3.  Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials.

Authors:  Sandeep Khurana; Pankaj Singh
Journal:  Liver Int       Date:  2006-10       Impact factor: 5.828

4.  Sertraline as a first-line treatment for cholestatic pruritus.

Authors:  Marlyn J Mayo; Iorna Handem; Sandra Saldana; Heidi Jacobe; Yonas Getachew; A John Rush
Journal:  Hepatology       Date:  2007-03       Impact factor: 17.425

5.  Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.

Authors:  M I Prince; A D Burt; D E J Jones
Journal:  Gut       Date:  2002-03       Impact factor: 23.059

6.  Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis.

Authors:  Jeff Browning; Burton Combes; Marlyn J Mayo
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

7.  Pain as a complication of use of opiate antagonists for symptom control in cholestasis.

Authors:  Christine A McRae; Martin I Prince; Mark Hudson; Christopher P Day; Oliver F W James; David E J Jones
Journal:  Gastroenterology       Date:  2003-08       Impact factor: 22.682

8.  PRURITUS AND JAUNDICE.

Authors:  N T MCPHEDRAN; R D HENDERSON
Journal:  Can Med Assoc J       Date:  1965-06-12       Impact factor: 8.262

9.  Natural history of pruritus in primary biliary cirrhosis.

Authors:  Jayant A Talwalkar; Enrico Souto; Roberta A Jorgensen; Keith D Lindor
Journal:  Clin Gastroenterol Hepatol       Date:  2003-07       Impact factor: 11.382

10.  Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice.

Authors:  Paul A Dawson; Jamie Haywood; Ann L Craddock; Martha Wilson; Mary Tietjen; Kimberly Kluckman; Nobuyo Maeda; John S Parks
Journal:  J Biol Chem       Date:  2003-06-20       Impact factor: 5.157
View more
  8 in total

1.  [Dyspnea, itching and depression in palliative medicine].

Authors:  M Mücke; R Conrad; M Bleckwenn; H Cuhls; L Radbruch; R Rolke
Journal:  Schmerz       Date:  2016-04       Impact factor: 1.107

2.  Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride.

Authors:  Shuhei Yoshikawa; Takeharu Asano; Mina Morino; Keita Matsumoto; Hitomi Kashima; Yudai Koito; Takaya Miura; Yuko Takahashi; Rumiko Tsuboi; Takehiro Ishii; Haruka Otake; Junichi Fujiwara; Masanari Sekine; Takeshi Uehara; Kazuhito Yuhashi; Satohiro Matsumoto; Shinichi Asabe; Hiroyuki Miyatani; Hirosato Mashima
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

3.  Bilirubin Induces Pain Desensitization in Cholestasis by Activating 5-Hydroxytryptamine 3A Receptor in Spinal Cord.

Authors:  Erliang Kong; Hongqian Wang; Xiaoqiang Wang; Yan Zhang; Jinmin Zhang; Weifeng Yu; Xudong Feng; Yuming Sun; Feixiang Wu
Journal:  Front Cell Dev Biol       Date:  2021-04-01

4.  A Macroporous Magnesium Oxide-Templated Carbon Adsorbs Shiga Toxins and Type III Secretory Proteins in Enterohemorrhagic Escherichia coli, Which Attenuates Virulence.

Authors:  Hidetada Hirakawa; Kazutomo Suzue; Motoyuki Uchida; Ayako Takita; Wataru Kamitani; Haruyoshi Tomita
Journal:  Front Microbiol       Date:  2022-05-06       Impact factor: 5.640

Review 5.  Review article: current and emerging therapies for the management of cirrhosis and its complications.

Authors:  Elliot B Tapper; Nneka N Ufere; Daniel Q Huang; Rohit Loomba
Journal:  Aliment Pharmacol Ther       Date:  2022-03-02       Impact factor: 9.524

Review 6.  Cholestasis beyond the Neonatal and Infancy Periods.

Authors:  Racha Khalaf; Claudia Phen; Sara Karjoo; Michael Wilsey
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2016-03-22

7.  BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.

Authors:  Vinod S Hegade; Stuart F W Kendrick; Robert L Dobbins; Sam R Miller; Duncan Richards; James Storey; George Dukes; Kim Gilchrist; Susan Vallow; Graeme J Alexander; Margaret Corrigan; Gideon M Hirschfield; David E J Jones
Journal:  BMC Gastroenterol       Date:  2016-07-19       Impact factor: 3.067

8.  Effect of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus on sleep disorders: a study protocol for single-arm, prospective, interventional study.

Authors:  Kazunori Yoh; Hiroki Nishikawa; Hirayuki Enomoto; Yoshinori Iwata; Akio Ishii; Yukihisa Yuri; Noriko Ishii; Yuho Miyamoto; Kunihiro Hasegawa; Chikage Nakano; Ryo Takata; Takashi Nishimura; Nobuhiro Aizawa; Yoshiyuki Sakai; Naoto Ikeda; Tomoyuki Takashima; Hiroko Iijima; Shuhei Nishiguchi
Journal:  BMJ Open Gastroenterol       Date:  2017-09-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.